OMRON (6645) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
8 Jul, 2026Executive summary
Consolidated revenue and profit increased for FY2025, led by strong Industrial Automation (IAB) performance driven by AI-related demand and customer base recovery, despite margin pressures.
FY2026 (and FY2027) outlook anticipates continued solid demand and higher sales and profits across all segments, with uncertainties from the Middle East and global economic conditions factored in.
Major accounting changes include a switch from US GAAP to IFRS and reclassification of DMB as a discontinued operation.
Dividend forecast raised to JPY 110 per share, up JPY 6 year-on-year, reflecting ongoing earnings growth.
Financial highlights
FY2025 net revenue rose 7.3% year-on-year to JPY 767.4 billion; operating income up 12.1% to JPY 59.9 billion.
Net income attributable to shareholders increased 75.1% to JPY 28.5 billion; EPS up 101.2 to JPY 188.02.
FY2026/27 plan: net revenue JPY 820 billion (+6.9% YoY), operating income JPY 62 billion (+13.9% YoY), net income JPY 27.5 billion.
ROE improved to 4.7% in FY2025; equity ratio projected to decrease slightly to 55.1%.
Free cash flow turned negative in FY2025 due to higher investment cash flow.
Outlook and guidance
FY2026/27 expects high growth in IAB, with strong AI and semiconductor demand, and solid performance in Healthcare, Social Systems, and Data Solutions.
Net income from continuing operations projected to rise 15.2% to JPY 45 billion.
Dividend payout to increase, targeting stable shareholder returns with DOE around 3%.
One-time expenses from DMB spin-off included in net income forecast.
Latest events from OMRON
- Profit and revenue soared in Q1, prompting an upward revision to full-year guidance.6645
Q1 2027 - Revenue and net sales up YoY, net income nearly doubled, and full-year guidance raised.6645
Q3 2026 - Sales up, profit down; guidance raised as automation and data outperform, healthcare lags.6645
Q2 2026 - Net income rebounded to ¥6.8bn as automation and device growth offset healthcare weakness.6645
Q1 2026 - Sales and profit fell sharply on restructuring costs, but full-year outlook is maintained.6645
Q1 2025 - Full-year profit guidance raised and dividends maintained despite lower sales and restructuring costs.6645
Q2 2025 - Profits surged on margin gains; FY2025/26 outlook cautious amid tariff risks.6645
Q4 2025 - Profit outlook raised as margin gains offset sales drop and restructuring costs.6645
Q3 2025